Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 7/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126972 | 0.91 | NAMPT (0.36) | TAS2R14PTGER2NAMPTPTGDR2POLB | |
| SCHEMBL4118130 | 0.90 | NAMPT (0.39) | TAS2R14PTGER2NAMPTPTGDR2ALDH1A1 | |
| SCHEMBL4126098 | 0.89 | NAMPT (0.39) | KEAP1NFE2L2NAMPTLMNAMAPT | |
| SCHEMBL3705293 | 0.88 | HTR2C (0.39) | KEAP1NFE2L2PTGER2NAMPTPOLB | |
| SCHEMBL3704890 | 0.88 | P2RX7 (0.34) | NAMPTPTGDR2LMNAALDH1A1 | |
| SCHEMBL4123658 | 0.88 | TAS2R14 (0.35) | KEAP1NFE2L2TAS2R14PTGER2NAMPT | |
| SCHEMBL3705296 | 0.88 | NAMPT (0.34) | KEAP1NFE2L2TAS2R14PTGER2NAMPT | |
| SCHEMBL3697696 | 0.87 | ALDH1A1 (0.38) | NFE2L2ALDH1A1MAPT | |
| SCHEMBL4135426 | 0.86 | NAMPT (0.36) | KEAP1NFE2L2TAS2R14PTGER2NAMPT | |
| SCHEMBL4131198 | 0.85 | NAMPT (0.39) | TAS2R14PTGER2NAMPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | KEAP1 1892/4885NFE2L2 2670/4885TAS2R14 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.